MedPath

The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis

Phase 2
Completed
Conditions
Osteoarthritis
Interventions
Biological: mesenchymal stem cell
Biological: Placebo
Registration Number
NCT01504464
Lead Sponsor
Royan Institute
Brief Summary

Osteoarthritis of the knee is one of the most common causes of disability among elderly. As the disease progresses the cartilage become frustrated, surrounding bone react to become thicker and inflammation occurs in subchondral bone seen in T2-weighted MRI as increase in signal density. Patients are treated initially by pain management. In patients who don't response to first line treatment invasive treatment like total knee replacement is done. The investigators designed this clinical study with the aim of evaluating therapeutic effects of intra-articular injection of bone marrow mesenchymal stem cells (BM-MSCs) in patients with severe knee osteoarthritis.

Detailed Description

This is single center, randomized, triple blind phase II clinical study. Patients will be divided into two groups of case and control. All subjects will undergo bone marrow aspiration. Mesenchymal stem cells will be isolated from bone marrow, cultured and transplanted back to the knee joint. Patients of case group will receive cell injection 1 and 4 months after bone marrow aspiration. Placebo will be administered in this group 6 months after the first injection. Patients of control group will receive placebo 1 and 4 months after bone marrow aspiration. They all receive cell injection 6 months after first placebo injection. Follow up visit will occur at 2 and 6 weeks, and 3 and 6 months after the first injection. Radiological exams will be performed before and 6 months after the first injection by MRI. Clinical quantitative assessment will measure joint function by the WOMAC index and pain by the visual analogue scale.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Osteoarthritis diagnosed by MRI
Exclusion Criteria
  • Pregnancy or lactating
  • Positive tests for HIV, HCV, HBV
  • Active neurologic disorder
  • End organ damage
  • Uncontrolled endocrine disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
mesenchymal stem cellmesenchymal stem cellPatients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
placeboPlaceboThe patients who are in control group and underwent placebo injection.
Primary Outcome Measures
NameTimeMethod
physical function improvement2weeks

Evaluation the physical function improvement Measured by WOMAC osteoarthritis index after cell injection.

change in pain density2 weeks

Evaluation the changing of pain density measured by Visual Analogue Scale after cell injection.

Secondary Outcome Measures
NameTimeMethod
joint swelling3months

Evaluation the joint swelling by physical examination after intra articular cell injection.

deterioration of joint function3months

Evaluation the deterioration of joint function by physical examination after intra articular cell injection.

Allergic reactions3months

Evaluation the allergic reactions like skin rash,skin erythema,dyspenea by physical examination after cell injection

joint erythema3months

Evaluation the joint erythem by physical examination after cell injection

Trial Locations

Locations (1)

Royan Institute

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath